Skip to main content

Table 2 Demographic, clinical, nutritional and analytical characteristics

From: Risk factors of hepatic function alterations in hospitalized adult patients treated with short-term parenteral nutrition receiving the same lipid composition at the same dose

Demographics Value   
 Men (n, %) 131 (72.4)   
 Age (years±SD) 66.57 ± 12.89   
 Weight (Kg ± SD) 68.79 ± 13.15   
 Height (cms ± SD) 166.00 ± 8.85   
Clinical data
 Cancer (patients: n, %) 121 (66.8)   
 Infection (patients: n, %) 67 (37.0)   
 Infection before PN treatment (focus: n, %) 35 (19.3)   
 Infection during PN treatment (focus: n, %) 50 (27.6)   
Type of infection:
 Abdominal (patients: n, %) 26 (30.9)   
 Surgical wound (patients: n, %) 17 (20.2)   
 Urinary (patients: n, %) 18 (21.4)   
 Pulmonary (patients: n, %) 9 (10.7)   
 Bacteriemia (patients: n, %) 14 (16.7)   
 Surgery (patients: n, %) 144 (79.6)   
 Surgery before PN treatment (patients: n, %) 139 (76.8)   
 Surgery during PN treatment (patients: n, %) 12 (6.6)   
Nutritional data
 Days of follow-up (days ±SD) 8.43 ± 6.64   
Analytical variables Beginning of PN
Average ± SD
End of follow-up
Average ± SD
t-pairs
p
 Gamma-glutamyl transferase (μkat/L) 0.55 ± 0.36 2.69 ± 2.49 0.000
 Alkaline phosphatase (μkat/L) 1.04 ± 0,33 1.97 ± 1.49 0.000
 Alanine aminotransferase (μkat/L) 0.32 ± 0.26 0.57 ± 0.92 0.000
 Total bilirubin (μmol/L) 6.98 ± 4.55 6.08 ± 5.37 0.029
 C-reactive protein (mg/L) 139.23 ± 111.99 99.72 ± 108.81 0.000
 Albumin (g/L) 28.44 ± 5.50 29.14 ± 5.55 0.061
 Leucocytes (x10E9/L) 10.79 ± 5.27 10.45 ± 4.89 0.427
 Lymphocytes (x10E9/L) 1.02 ± 0.52 1.31 ± 1.21 0.000
 Triglycerides (mmol/L) 1.42 ± 0.66 1.85 ± 0,72 0.000
 Glucose (mmol/L) 7.02 ± 2.44 6.44 ± 1.81 0.000
 Creatinine (μmol/L) 78.94 ± 53.61 71.27 ± 46.69 0.000
 Platelets (x10E9/L) 270.01 ± 108.14 370.98 ± 159.14 0.000
 Prothrombin time 1.18 ± 0,15 1.16 ± 0,13 0.014
  1. SD standard deviation